{
    "clinical_study": {
        "@rank": "124387", 
        "arm_group": [
            {
                "arm_group_label": "Supplement + Expanded Interview", 
                "arm_group_type": "Experimental", 
                "description": "Supplement, 2 tablets sublingually 3 times a day for 2 weeks."
            }, 
            {
                "arm_group_label": "Placebo + Standard Interview", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, 2 tablets sublingually 3 times a day for 2 weeks."
            }, 
            {
                "arm_group_label": "Supplement + Standard Interview", 
                "arm_group_type": "Experimental", 
                "description": "Supplement, 2 tablets sublingually 3 times a day for 2 weeks."
            }, 
            {
                "arm_group_label": "Placebo + Expanded Interview", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, 2 tablets sublingually 3 times a day for 2 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effects of a widely available over the\n      counter supplement marketed for heartburn symptoms on symptoms and health-related quality of\n      life in patients with gastroesophageal reflux disease (GERD).  This study is designed as a\n      pilot trial to assess safety and feasibility and to provide preliminary estimates of effect\n      sizes."
        }, 
        "brief_title": "Response to Supplement and Placebo in GERD", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Gastroesophageal Reflux Disease (GERD)", 
            "Heartburn", 
            "Dyspepsia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Gastroesophageal Reflux", 
                "Heartburn"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult humans age 18-80.\n\n          -  Fluency in written and spoken English.\n\n          -  Heartburn symptoms 3 or more days per week for the past month.\n\n        Exclusion Criteria:\n\n          -  Individuals taking a proton pump inhibitor (PPI) or H2 receptor blocker with a dose\n             change within 2 weeks of the initial study visit.\n\n          -  Individuals with Crohns disease, systemic sclerosis, known active ulcer disease,\n             gastric cancer, Barrett's esophagitis\n\n          -  Significant pain or difficulty with swallowing\n\n          -  Heavy alcohol use (defined by > 6 drinks/week for women and > 13 drinks/week for men)\n\n          -  Concurrent pregnancy\n\n          -  Dementia\n\n          -  Uncontrolled psychiatric disease\n\n          -  Individuals unable to complete a paper symptom diary for 6 of 7 days prior to their\n             baseline visit\n\n          -  Subjects whose symptoms are predominantly dyspeptic more than heartburn or reflux\n\n          -  Subjects who have used homeopathy for GI symptoms or have received constitutional\n             homeopathic treatment within the past 2 weeks\n\n          -  Subjects taking herbal products or other supplements for GERD or dyspepsia related\n             symptoms (includes peppermint oil)\n\n          -  Subjects who have taken > 12 doses of NSAIDS within the prior 30 days (aspirin \u2264 325\n             mg daily is allowed)\n\n          -  Subjects with lactose intolerance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915173", 
            "org_study_id": "2012-P-000409", 
            "secondary_id": "IND 117358"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Supplement + Expanded Interview", 
                    "Supplement + Standard Interview"
                ], 
                "description": "Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C", 
                "intervention_name": "Supplement", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo + Standard Interview", 
                    "Placebo + Expanded Interview"
                ], 
                "description": "Lactose tablets", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Supplement + Expanded Interview", 
                    "Placebo + Expanded Interview"
                ], 
                "intervention_name": "Expanded Interview", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "Placebo + Standard Interview", 
                    "Supplement + Standard Interview"
                ], 
                "intervention_name": "Standard Interview", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gastroesophageal reflux disease (GERD)", 
            "Heartburn", 
            "Dyspepsia"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02215"
                }, 
                "name": "Beth Israel Deaconess Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Response to Supplement and Placebo in GERD", 
        "overall_official": {
            "affiliation": "Beth Israel Deaconess Medical Center", 
            "last_name": "Michelle Dossett, MD, PhD, MPH", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "No major adverse events (as defined by FDA criteria) attributed to the study intervention and no statistically significant increase in minor adverse events between the intervention and placebo arms.", 
            "measure": "Safety - number of major and minor adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "2 week follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915173"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Based on daily symptom diary scores.", 
                "measure": "Percent of subjects with a 50% or greater decrease in heartburn symptom severity", 
                "safety_issue": "No", 
                "time_frame": "Second week of the trial compared to pre-trial baseline"
            }, 
            {
                "measure": "Percent improvement in disease-specific and overall quality of life", 
                "safety_issue": "No", 
                "time_frame": "Two weeks (baseline to follow-up)"
            }
        ], 
        "source": "Beth Israel Deaconess Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beth Israel Deaconess Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}